Chinese researchers have detailed the discovery of a novel benzochalcone derivative being developed for the treatment of gastric cancer.

Investigators from the University of Copenhagen, Denmark have developed a cell line engineered to express bone morphogenetic protein 2 (BMP-2) and key extracellular matrix genes and critical factors that regulate and support human hematopoiesis. The findings were reported in the Oct. 12, 2022, issue of Science Translational Medicine. One of the clinical applications that the research team is interested in involves exploiting the MSOD-B hOss as a tumor model for bone colonization in the context of various cancers.

Odyssey Therapeutics Inc. closed a hefty $168 million series B round to progress multiple small-molecule and protein-based drug discovery and development programs in autoimmune disease and cancer.

About 50% of patients with lung cancer present with metastatic disease; researchers have shown that breast cancer metastasis-suppressor 1 (BRMS1) suppresses metastases in non-small-cell lung cancer and other solid tumors due to its ability to function in a multiprotein histone deacetylase transcriptional corepressor complex or as an E3 ligase to control the degradation of p300 acetyltransferase.

Tavros Therapeutics Inc. and Vividion Therapeutics Inc., a subsidiary of Bayer AG, have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term.